Stable quality and accurate results. These six words are written on the front page of every product manual of Jinyuankang Biotechnology, and also engraved in the 26 year development gene of this enterprise.
The spring breeze of April brushes over the hot soil where Jinyuankang Biotechnology is located. On April 17, 2026, Jinyuankang Biotechnology welcomed a group of important guests, including President Fan Jianping of Shenzhen University of Technology, Director Han Wenxuan of the Party and Government Office, Director Zhang Xiao of the Party Committee Propaganda Department, Deputy Director Liu Kuan of the Finance Department, Director Guo Cheng of the Admissions Department, and Assistant Director Wang Yajie of the School of Life and Health. This is not only a high-level visit in the daily reception of enterprises, but also a deep dialogue between industry leaders and national strategic scientific and technological forces.
On the one hand, it is the hidden champion who has been deeply cultivating the core raw materials in the upstream of biomedicine for 26 years; On the other hand, it represents the innovative source of the cutting-edge exploration spirit of new research-oriented universities. The handshake between the two sides points to a common proposition: how to truly enable China's biomanufacturing to have autonomous capabilities starting from the "core".
Note: Shenzhen University of Technology is a new type of research-oriented university built from a high starting point. Its core educational characteristics are "integrating industry and education, integrating science and education to run a university, cross disciplinary construction of majors, and the integration of three colleges (college, research institute, academy) to cultivate talents".
1、 The confidence in the exhibition hall: from a bottle of serum to a set of ecology
The first stop of the inspection team is the exhibition hall of Jin Yuankang. General Manager Su Ye introduced the real background of the enterprise to the customer system.
Over the past 26 years, Jinyuankang has grown from a bottle of serum to a leading industry in the upstream core raw materials of domestic biopharmaceuticals. The industrial positioning of the enterprise is clear and restrained: it does not blindly extend downstream, but focuses on the key link of cell culture, and builds a complete industrial platform covering research and development, large-scale production, full chain quality control, and professional services.
More noteworthy is the strategic evolution that Jin Yuankang is undergoing - a profound transformation from a single product supplier to a "one-stop solution provider for cell culture systems". This means that Jinyuankang not only provides high-quality "core components" such as serum and culture medium, but also provides customers with overall empowerment from cell line screening, culture medium optimization to process amplification based on deep process understanding, truly becoming an "external extended R&D department" for customers' production processes.
The set of hardcore assets displayed in the exhibition hall confirms Jinyuankang's confidence as an industry leader: 50+industrial cell line library, 300+scientific research cell line library, the industry's only B+A-level clean production workshop, a biosafety laboratory that meets P2 standards, fully automated production lines, and a global traceability system. These capabilities enable Jinyuankang to seamlessly integrate in-depth technical analysis and process optimization services into the entire product delivery cycle, jointly ensuring the stability and efficiency of customer production.
2、 Entering P2 Laboratory: On site Witness of Hardcore R&D Capability
After leaving the exhibition hall, the inspection team arrived at Jinyuankang's technology center and visited the biosafety laboratory that meets the P2 standard on site.
P2 laboratory is one of the core hubs of enterprise R&D system. Here, the R&D team of Jinyuankang is conducting a series of cutting-edge explorations around cell culture, serum optimization, and culture medium development. The members of the inspection team learned about the layout, safety control procedures, and daily operation of the laboratory through the observation window. The R&D personnel introduced the specific work of the laboratory in cell line screening, process validation, etc., demonstrating the standardized operation and rigorous attitude of the enterprise under the biosafety level.
As the only enterprise in the industry with a B+A-level clean production workshop, Jinyuankang's investment in hardware facilities is in line with its commitment to "stable quality and accurate results". The P2 laboratory is not only a physical space for research and development innovation, but also a key verification platform for enterprises to transform cutting-edge technologies into reliable products. The inspection team expressed concern about the continuous investment of enterprises in research and development infrastructure, and the two sides also had on-site exchanges on the technical difficulties in the research and development of core biopharmaceutical raw materials.
3、 Sincerely seeking deep innovation system cooperation: from "selling products" to "mutual strategic pivot"
If visiting the exhibition hall is a way to show off one's family background, then the subsequent communication is a way to show sincerity. Jinyuankang has made it clear that the company's visit is driven by clear industrial needs and strategic sincerity, seeking to establish a new type of cooperation that deeply integrates and serves as a strategic pivot with the Shenzhen innovation system, which represents the country's strategic scientific and technological strength.
Jinyuankang's vision is not just to be an excellent raw material supplier. The company explicitly proposes to become a leading global platform and standard leader in cell culture ecology. By building an open ecosystem that integrates technology, products, information, and supply chain services, linking the entire biopharmaceutical industry chain, and ultimately aspiring to lead or deeply participate in the development of relevant standards for core biopharmaceutical raw materials and processes, China aims to enhance its voice in the global industrial chain.
This ambition needs to resonate with top research forces on the same frequency. And Shenzhen University of Technology is the ideal companion in the eyes of Jin Yuankang. As emphasized in the internal strategy of the company, "Mastering core technologies and leading industry development." This is not only a slogan, but also a future oriented action plan for Jinyuankang. And this in-depth exchange with Shenzhen University of Technology is an important step for Jinyuankang to put this vision into action.
4、 One reception, triple significance: setting the tone for Jin Yuankang's future
Looking back at the inspection reception on April 17th, its significance to Jinyuankang Biotechnology goes far beyond a successful brand showcase. It anchors at least three key directions for the future development of the enterprise:
Firstly, it opens up new imaginative space for deep cooperation between schools and enterprises. Previously, Jinyuankang mainly dealt with customers and suppliers, and there was still a lack of systematic interaction with top research universities. The visit of Shenzhen University of Technology has shown enterprises more possibilities for industry university research collaboration. Jinyuankang's market network covers three major sectors: vaccines, biopharmaceuticals, and scientific research. This constitutes a solid foundation and market reach for the enterprise, and is also the best channel for any innovative technology to achieve industrial transformation. The cutting-edge achievements of universities are expected to be accelerated through Jinyuankang's industrial platform.
Secondly, it further strengthened Jinyuankang's strategic determination to lead with technology. As a company that has grown from large-scale industrial manufacturing, Jin Yuankang has gained a clearer understanding through this exchange with cutting-edge scientists that the true moat is not production capacity, but deep technological capabilities based on cell biology, genomics, and synthetic biology. The company will continue to increase its research and development investment in cutting-edge directions, define standards with technology, and lead the industry with standards.
Thirdly, it has pointed out the path of "open innovation" for the future development of Jinyuankang. To become a platform based enterprise in the cell culture ecosystem, Jinyuankang must actively connect various forces such as universities, research institutes, and innovative pharmaceutical companies. The visit of Shenzhen University of Technology provides an important opportunity for Jin Yuankang to open this door. The enterprise will take this as a new starting point and steadfastly pursue the path of open innovation.
At the end: A handshake, a possibility
When bidding farewell to the delegation from Shenzhen University of Technology, the sunshine was shining on every corner of Jin Yuankang. The factory with a B+A clean standard operates quietly, producing core raw materials for hundreds of enterprises across the country every day.
At this moment, behind it, a new story is brewing: when industry leaders and national strategic technological forces truly grasp hands, the "upstream core" of China's biopharmaceutical industry may usher in a historic turning point from catching up to definition.
Jinyuankang Biotechnology has already departed.
Scan to follow